Brief: Index Pharmaceuticals Enters Agreement With Parexel Biotech

Flerie AB

30/03/2021 07:01

March 30 (Reuters) - InDex Pharmaceuticals Holding AB
 INDEX.ST :
    * INDEX PHARMACEUTICALS ENTERS AGREEMENT WITH PAREXEL
BIOTECH FOR
PHASE III CLINICAL STUDY OF COBITOLIMOD FOR ULCERATIVE COLITIS
    * STUDY WILL EVALUATE EFFICACY AND SAFETY OF DRUG CANDIDATE
COBITOLIMOD FOR TREATMENT OF MODERATE TO SEVERE LEFT-SIDED
ULCERATIVE COLITIS.

Source text for Eikon:  ID:nWkr13jYsK 
Further company coverage:  INDEX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))